Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

870
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
870

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pathological Predictors of Limited Salvage Radiotherapy Efficacy After Radical Prostatectomy: Central Review of JCOG0401.

Cancers·2026
Same author

Volume-adjusted p2PSA-derived indices for predicting prostate cancer: the PROPHET study.

International journal of clinical oncology·2026
Same author

GWAS from a multicenter prospective study of radium-223 in bone-metastatic castration-resistant prostate cancer.

EJNMMI research·2026
Same author

Quantifying ergonomic challenges for urologists operating flexible ureteroscopes through artificial intelligence-based posture estimation.

World journal of urology·2026
Same author

Genetic Predictors of Progression and Skin Rash in Japanese mCSPC Patients Treated With Apalutamide: CUARTET Study.

Cancer science·2026
Same author

Sustainable and reusable antibacterial aerogels constructed from surface-quaternized cellulose nanofibrils for effective oil-water separation.

Carbohydrate polymers·2026
Same journal

Metformin and Flutamide Combination Therapy's Efficacy and Safety in Prostate Cancer Cell Lines.

Prostate cancer·2026
Same journal

In Vitro Effects of Cabazitaxel and Menadione on Cell Growth, Metabolism, and Transcriptomic Profile of Human Prostate Cancer Cell Lines.

Prostate cancer·2026
Same journal

Determinants of the Cost of Illness in Iranian Prostate Cancer Patients.

Prostate cancer·2026
Same journal

The Impact of Tumor Microenvironmental Acidity on Bicalutamide Sensitivity in Prostate Cancer Cells.

Prostate cancer·2026
Same journal

Correlating Histological Results and Total Serum Levels of the Prostate-Specific Antigen Among Patients in Southwestern Uganda.

Prostate cancer·2026
Same journal

Change in Clinical Management of Localized Prostate Cancer Patients at a Tertiary Medical Center as a Result of SARS-CoV-2 (COVID-19).

Prostate cancer·2026
See all related articles

Related Experiment Video

Updated: May 6, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K

Real-World Treatment Patterns Before and After Metastatic Castration-Resistant Prostate Cancer in Japan:

Masaki Shiota1, Linghua Xu2, Tomoyo Oguri3

  • 1Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, kyushu-u.ac.jp.

Prostate Cancer
|March 9, 2026
PubMed
Summary
This summary is machine-generated.

In Japan, vintage hormone therapy was the most common pretreatment for metastatic castration-resistant prostate cancer (mCRPC). Androgen receptor signaling inhibitors (ARSIs) are increasingly used as first-line mCRPC treatments, replacing older therapies.

Keywords:
Japanese prostate cancer patientscastration-sensitive prostate cancerdatabase analysisreal-worldtreatment sequence

More Related Videos

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

9.7K
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

984

Related Experiment Videos

Last Updated: May 6, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K
Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

9.7K
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

984

Area of Science:

  • Oncology
  • Urology
  • Pharmacology

Background:

  • Treatment options for metastatic castration-resistant prostate cancer (mCRPC) have expanded since 2014.
  • Limited data exists on drug treatment sequences in Japanese clinical practice for mCRPC.
  • This study addresses the need for understanding mCRPC treatment patterns in Japan.

Purpose of the Study:

  • To investigate the current landscape of mCRPC treatments in Japan.
  • To analyze the transition of prior and post-mCRPC treatment sequences.
  • To identify trends in mCRPC drug utilization.

Main Methods:

  • Utilized Medical Data Vision's medical record database in Japan.
  • Extracted data for patients diagnosed with mCRPC between January 2015 and December 2022.
  • Analyzed treatment sequences before and after mCRPC diagnosis.

Main Results:

  • Analyzed 4967 mCRPC patients.
  • Most common pretreatment: vintage hormone therapy (77.1%).
  • Most common first-line mCRPC treatments: enzalutamide (43.1%), abiraterone (28.3%), docetaxel (10.7%).
  • Vintage hormone therapy use decreased annually, replaced by ARSIs.
  • When prior ARSI treatment was used, docetaxel or another ARSI were common first-line choices.

Conclusions:

  • Vintage hormone therapy remains a common pretreatment for mCRPC in Japan.
  • Androgen receptor signaling inhibitors (ARSIs) are the predominant first-line treatments for mCRPC.
  • Treatment patterns are shifting towards ARSIs over time.